Bay Street News

ProMetic reports its 2015 fourth quarter and year end highlights and financial results

Clinical efficacy in humans confirmed for PBI-4050
ProMetic’s plasminogen phase 2/3 clinical trial initiated
ProMetic’s IVIG phase 3 clinical trial initiated
Significant expansion of plasma derived therapeutics’ manufacturing capacity
2015 fourth quarter revenues of $14.1 million and…